File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony–Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells

TitleConsolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony–Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells
Authors
KeywordsGD2 monoclonal antibody
Neuroblastoma
Natural killer cells
Immunotherapy
Autologous transplantation
Issue Date2017
Citation
Biology of Blood and Marrow Transplantation, 2017, v. 23, n. 11, p. 1910-1917 How to Cite?
Abstract© 2017 The American Society for Blood and Marrow Transplantation. The treatment of pediatric high-risk neuroblastoma is intensive and multimodal. Despite the introduction of immunotherapy for minimal residual disease, survival rates remain suboptimal and new therapies are needed. As part of a phase 2 trial, we are using a consolidation therapy regimen that combines a busulfan/melphalan conditioning schema, autologous hematopoietic cell transplantation (AHCT), and experimental immunotherapy with hu14.18K322A (a humanized anti-GD2 monoclonal antibody), granulocyte-macrophage colony–stimulating factor (GM-CSF), and IL-2, with or without the adoptive transfer of haploidentical natural killer cells (NKs). Here we report on 30 patients who have undergone AHCT with this experimental immunotherapy regimen, 21 of whom received haploidentical NKs. The median time to neutrophil engraftment was 13 days (range, 10 to 28 days) and to platelet engraftment of at least 20 × 103/mm3 was 36.5 days (range, 0 to 102 days); no clinical difference was seen in those who did or did not receive NKs. Eight patients developed veno-occlusive disease, with 3 having multiorgan dysfunction. Toxicities were similar for patients who did or did not receive NKs. We conclude that this consolidation regimen is feasible and has an acceptable acute toxicity profile.
Persistent Identifierhttp://hdl.handle.net/10722/294517
ISSN
2020 Impact Factor: 5.742
2020 SCImago Journal Rankings: 2.301
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTalleur, Aimee C.-
dc.contributor.authorTriplett, Brandon M.-
dc.contributor.authorFederico, Sara-
dc.contributor.authorMamcarz, Ewelina-
dc.contributor.authorJanssen, William-
dc.contributor.authorWu, Jianrong-
dc.contributor.authorShook, David-
dc.contributor.authorLeung, Wing-
dc.contributor.authorFurman, Wayne L.-
dc.date.accessioned2020-12-03T08:22:55Z-
dc.date.available2020-12-03T08:22:55Z-
dc.date.issued2017-
dc.identifier.citationBiology of Blood and Marrow Transplantation, 2017, v. 23, n. 11, p. 1910-1917-
dc.identifier.issn1083-8791-
dc.identifier.urihttp://hdl.handle.net/10722/294517-
dc.description.abstract© 2017 The American Society for Blood and Marrow Transplantation. The treatment of pediatric high-risk neuroblastoma is intensive and multimodal. Despite the introduction of immunotherapy for minimal residual disease, survival rates remain suboptimal and new therapies are needed. As part of a phase 2 trial, we are using a consolidation therapy regimen that combines a busulfan/melphalan conditioning schema, autologous hematopoietic cell transplantation (AHCT), and experimental immunotherapy with hu14.18K322A (a humanized anti-GD2 monoclonal antibody), granulocyte-macrophage colony–stimulating factor (GM-CSF), and IL-2, with or without the adoptive transfer of haploidentical natural killer cells (NKs). Here we report on 30 patients who have undergone AHCT with this experimental immunotherapy regimen, 21 of whom received haploidentical NKs. The median time to neutrophil engraftment was 13 days (range, 10 to 28 days) and to platelet engraftment of at least 20 × 103/mm3 was 36.5 days (range, 0 to 102 days); no clinical difference was seen in those who did or did not receive NKs. Eight patients developed veno-occlusive disease, with 3 having multiorgan dysfunction. Toxicities were similar for patients who did or did not receive NKs. We conclude that this consolidation regimen is feasible and has an acceptable acute toxicity profile.-
dc.languageeng-
dc.relation.ispartofBiology of Blood and Marrow Transplantation-
dc.subjectGD2 monoclonal antibody-
dc.subjectNeuroblastoma-
dc.subjectNatural killer cells-
dc.subjectImmunotherapy-
dc.subjectAutologous transplantation-
dc.titleConsolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony–Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1016/j.bbmt.2017.07.011-
dc.identifier.pmid28733263-
dc.identifier.pmcidPMC5682204-
dc.identifier.scopuseid_2-s2.0-85027684847-
dc.identifier.volume23-
dc.identifier.issue11-
dc.identifier.spage1910-
dc.identifier.epage1917-
dc.identifier.eissn1523-6536-
dc.identifier.isiWOS:000416196600015-
dc.identifier.issnl1083-8791-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats